Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.

Genes, chromosomes & cancer - 1 May 2017

Gow Chien-Hung, Chang Hou-Tai, Lim Chor-Kuan, Liu Chao-Yu, Chen Jin-Shing, Shih Jin-Yuan

Abstract excerpt

HER2 is a major proliferative driver in lung cancer. HER2 gene aberrations impact the prognosis of lung adenocarcinoma (ADC). A one-step reverse transcription-polymerase chain reaction was performed using RNA samples from 888 Asian lung cancer patients to detect HER2, EGFR, KRAS, ALK, and ROS1 mutations. The demographic data and treatment outcomes of HER2 mutation-positive lung ADC patients were analyzed and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Neoplasm Staging

Share to Receptor, ErbB-2

Share to Survival Rate

Source

Identifiers

PMID: 28063177
DOI: 10.1002/gcc.22442

Genes

EGFR
ALK
KRAS
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.PMID 28063177Read ↗

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Semantic proximity Read ↗

Treatment Outcome and Clinical Characteristics of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in ChinaSemantic proximity Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.Semantic proximity Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.Semantic proximity Read ↗

Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.Semantic proximity Read ↗

Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.Semantic proximity Read ↗

The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.Semantic proximity Read ↗

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.